Literature DB >> 15126374

A retinoid-related molecule that does not bind to classical retinoid receptors potently induces apoptosis in human prostate cancer cells through rapid caspase activation.

Richard G Keedwell1, Yi Zhao, Lisette A Hammond, Suofu Qin, Kwok-Yin Tsang, Armin Reitmair, Yanira Molina, Yumiko Okawa, Larissa I Atangan, Dixie-Lee Shurland, Kaisheng Wen, D Michael A Wallace, Roger Bird, Roshantha A S Chandraratna, Geoffrey Brown.   

Abstract

Synthetic retinoid-related molecules, such as N-(4-hydroxyphenyl)retinamide (fenretinide) and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) induce apoptosis in a variety of malignant cells. The mechanism(s) of action of these compounds does not appear to involve retinoic acid receptors (RARs) and retinoid X receptors (RXRs), although some investigators disagree with this view. To clarify whether some retinoid-related molecules can induce apoptosis without involving RARs and/or RXRs, we used 4-[3-(1-heptyl-4,4-dimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-3-oxo-E-propenyl] benzoic acid (AGN193198) that neither binds effectively to RARs and RXRs nor transactivates in RAR- and RXR-mediated reporter assays. AGN193198 potently induced apoptosis in prostate, breast, and gastrointestinal carcinoma cells and in leukemia cells. AGN193198 also abolished growth (by 50% at 130-332 nM) and induced apoptosis in primary cultures established from prostatic carcinoma (13 patients) and gastrointestinal carcinoma (1 patient). Apoptosis was induced rapidly, as indicated by mitochondrial depolarization and DNA fragmentation. Molecular events provoked by AGN193198 included activation of caspase-3, -8, -9, and -10 (by 4-6 h) and the production of BID/p15 (by 6 h). These findings show that caspase-mediated induction of apoptosis by AGN193198 is RAR/RXR-independent and suggest that this compound may be useful in the treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126374     DOI: 10.1158/0008-5472.can-03-2763

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Highly twisted adamantyl arotinoids: synthesis, antiproliferative effects and RXR transactivation profiles.

Authors:  Santiago Pérez-Rodríguez; Maria A Ortiz; Raquel Pereira; Fátima Rodríguez-Barrios; Angel R de Lera; F Javier Piedrafita
Journal:  Eur J Med Chem       Date:  2009-01-20       Impact factor: 6.514

2.  Suofu Qin's work on studies of cell survival signaling in cancer and epithelial cells.

Authors:  Suofu Qin
Journal:  World J Biol Chem       Date:  2010-12-26

3.  PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation.

Authors:  Jingbo Qiao; Pritha Paul; Sora Lee; Lan Qiao; Erlena Josifi; Joshua R Tiao; Dai H Chung
Journal:  Biochem Biophys Res Commun       Date:  2012-07-02       Impact factor: 3.575

4.  Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells.

Authors:  Hosea F Huang; Thomas F Murphy; Ping Shu; Arnold B Barton; Beverly E Barton
Journal:  Mol Cancer       Date:  2005-01-12       Impact factor: 27.401

5.  Retinoic acid receptor α expression exerts an anti-apoptosis effect on PC12 cells following oxygen-glucose deprivation.

Authors:  Wanliang Dong; Yuankun Zhang
Journal:  Exp Ther Med       Date:  2018-08-22       Impact factor: 2.447

6.  α-Lithiation and electrophilic substitution of 1,4,4-trimethyl-3,4-dihydroquinolin-2-one.

Authors:  Bouclé Sébastien; Guillard Jérôme; Viaud-Massuard Marie-Claude
Journal:  Molecules       Date:  2010-10-29       Impact factor: 4.411

7.  An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium.

Authors:  R G Keedwell; Y Zhao; L A Hammond; K Wen; S Qin; L I Atangan; D-L Shurland; D M A Wallace; R Bird; A Reitmair; R A S Chandraratna; G Brown
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.